PAVmed Q2 EPS $(0.09) Beats $(0.19) Estimate, Sales $166.00K Miss $520.00K Estimate
Portfolio Pulse from Happy Mohamed
PAVmed reported Q2 losses of $(0.09) per share, beating the analyst consensus estimate of $(0.19) by 52.63%. However, the company's quarterly sales of $166.00K missed the analyst consensus estimate of $520.00K by 68.08%.
August 16, 2023 | 4:21 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
PAVmed's Q2 earnings beat estimates but sales missed, which could lead to mixed market reactions.
PAVmed's earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. These two factors could offset each other, leading to a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100